SG
LENZ

StoneX Group’s LENZ Therapeutics LENZ Stock Holding History

StoneX Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,957
Closed -$37.7K – 534
2022
Q2 		$37.7K Buy
+1,957
New +$43.6K 0.01% 414

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

StoneX Group's LENZ Position: Q3 2022 in Review

StoneX Group sold out of LENZ Therapeutics (LENZ) in Q3 2022, closing a stake of 1,957 shares — an estimated $37.7K sold.

StoneX Group first reported a position in LENZ in Q2 2022 and held it in 1 quarter. The position peaked at $37.7K in Q2 2022. 63 funds tracked by Wall St. Rank hold LENZ as of Q3 2022.

  • StoneX Group reported no remaining LENZ Therapeutics position as of Q3 2022 after selling out during the quarter.
  • StoneX Group sold 1,957 LENZ Therapeutics shares in Q3 2022, an estimated $37.7K.
  • StoneX Group first reported a position in LENZ Therapeutics in Q2 2022 and held it in 1 quarter.
  • StoneX Group's LENZ Therapeutics position peaked at $37.7K in Q2 2022.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.